Bristol Myers Gets EC Approval for Onureg in Acute Myeloid Leukemia
June 18 2021 - 10:22AM
Dow Jones News
By Michael Dabaie
Bristol Myers Squibb said the European Commission granted full
marketing authorization for Onureg as a maintenance therapy in
acute myeloid leukemia.
Bristol Myers said the authorization approves use of Onureg in
all European Union member states, as well as Norway, Iceland and
Liechtenstein.
In the pivotal QUAZAR AML-001 study, Onureg significantly
improved overall survival and relapse-free survival in patients
with acute myeloid leukemia, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 18, 2021 10:08 ET (14:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024
